|Bid||0.00 x 1300|
|Ask||0.00 x 1000|
|Day's range||89.27 - 89.99|
|52-week range||74.09 - 94.26|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||9.23|
|Forward dividend & yield||3.33 (3.70%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||104.25|
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolioAddition of Mycamine® will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar)